PT - JOURNAL ARTICLE AU - Verena Zuber AU - Alan Cameron AU - Evangelos P. Myserlis AU - Leonardo Bottolo AU - Israel Fernandez-Cadenas AU - Stephen Burgess AU - Christopher D. Anderson AU - Jesse Dawson AU - Dipender Gill TI - Leveraging genetic data to elucidate the relationship between Covid-19 and ischemic stroke AID - 10.1101/2021.02.25.21252441 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.21252441 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252441.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252441.full AB - Background The relationship between coronavirus disease 2019 (Covid-19) and ischemic stroke is poorly defined. We aimed to leverage genetic data to investigate reported associations.Methods Genetic association estimates for liability to Covid-19 and cardiovascular traits were obtained from large-scale consortia. Analyses primarily focused on critical Covid-19, defined as hospitalization with Covid-19 requiring respiratory support or resulting in death. Cross-trait linkage disequilibrium score regression was used to estimate genetic correlations of critical Covid-19 with ischemic stroke, other related cardiovascular outcomes, and risk factors common to both Covid-19 and cardiovascular disease (body mass index, smoking and chronic inflammation, estimated using C-reactive protein). Mendelian randomization analysis was performed to investigate whether liability to critical Covid-19 was associated with increased risk of any of the cardiovascular outcomes for which genetic correlation was identified.Results There was evidence of genetic correlation between critical Covid-19 and ischemic stroke (rg=0.29, FDR p-value=4.65×10−3), body mass index (rg=0.21, FDR-p-value=6.26×10−6) and C-reactive protein (rg=0.20, FDR-p-value=1.35×10−4), but none of the other considered traits. In Mendelian randomization analysis, liability to critical Covid-19 was associated with increased risk of ischemic stroke (odds ratio [OR] per logOR increase in genetically predicted critical Covid-19 liability 1.03, 95% confidence interval 1.00-1.06, p-value=0.03). Similar estimates were obtained when considering ischemic stroke subtypes. Consistent estimates were also obtained when performing statistical sensitivity analyses more robust to the inclusion of pleiotropic variants, including multivariable Mendelian randomization analyses adjusting for potential genetic confounding through body mass index, smoking and chronic inflammation. There was no evidence to suggest that genetic liability to ischemic stroke increased the risk of critical Covid-19.Conclusions These data support that liability to critical Covid-19 is associated with an increased risk of ischemic stroke. The host response predisposing to severe Covid-19 is likely to increase the risk of ischemic stroke, independent of other potentially mitigating risk factors.Competing Interest StatementCDA receives sponsored research support from the American Heart Association, Massachusetts General Hospital, and Bayer AG, and has consulted for ApoPharma, Inc. DG is employed part-time by Novo Nordisk. The remaining authors have no conflicts of interest to declare.Funding StatementVZ is supported by UK Dementia Research Institute at Imperial College London, which is funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK (MC_PC_17114). LB acknowledges the MRC grant MR/S02638X/1, The BHF-Turing Cardiovascular Data Science Awards 2017 and The Alan Turing Institute under the Engineering and Physical Sciences Research Council grant EP/N510129/1. IF-C is supported by Inmungen-Cov2 project, Centro Superior de Investigaciones Cientificas (CSIC). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This research was supported by the UKRI Medical Research Council [MC_UU_00002/7] and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. CDA is supported by the National Institutes of Health of the United States (R01NS103924, U01NS069763). DG is supported by the British Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215) and by a National Institute for Health Research Clinical Lectureship at St. George's, University of London (CL-2020-16-001). This research was funded in part by the Wellcome Trust. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All genetic association data used in this work are publicly accessible. Appropriate patient consent and ethical approval had been obtained in the original studies from which they were obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genetic association data used in this work are publicly accessible. Statistical code related to the analyses performed in the current study is freely available from Github (https://github.com/verena-zuber/covid19_and_stroke).BMIBody mass indexCIConfidence intervalCovid-19Coronavirus disease 2019CRPC-reactive proteinCVDCardiovascular diseaseFDRFalse discovery rateIVWInverse-variance weightedLDSCLinkage disequilibrium score regressionMRMendelian randomizationOROdds ratiosSARS-CoV-2Severe acute respiratory syndrome coronavirus 2